By PR Newswire
July 21, 2026 | 15:08
Fox ESS launched POWER BEAST in Australia, a scalable commercial and industrial energy storage solution combining its H3 Plus Hybrid Inverter with the CQ7 High Voltage Storage Battery.
By PR Newswire
July 21, 2026 | 15:03
Medtrum advanced its 300U tubeless patch pump toward a German launch, a higher-capacity option that expands the TouchCare Nano System and supports the company's continued growth across Europe.
By PR Newswire
July 21, 2026 | 14:57
Antengene Corporation, listed under stock code 6996.HK, announced poster presentations of its ATG-022 and ATG-037 drug candidates at the 2026 European Society for Medical Oncology congress.
By PR Newswire
July 21, 2026 | 14:52
SPTel received Frost and Sullivan's 2026 Singapore Company of the Year recognition for its leadership in quantum-safe network services, highlighting its commercial deployment of national-scale quantum-safe communications infrastructure.
By PR Newswire
July 21, 2026 | 14:44
CNPC launched China's first full-chain green, low-carbon ethylene project, according to a China Daily report, marking a milestone in the country's petrochemical decarbonisation efforts.
By PR Newswire
July 21, 2026 | 14:41
Telix Pharmaceuticals dosed the first patient in its Phase 3 LUTEON trial evaluating TLX250-Tx for relapsed or recurrent clear cell renal cell carcinoma, marking the first Phase 3 study of a CAIX-targeted radiopharmaceutical in this cancer type.
By PR Newswire
July 21, 2026 | 11:28
Lundbeck announced the last patient has been randomized in DEEp OCEAN, a global Phase III trial evaluating bexicaserin for seizures in developmental and epileptic encephalopathies.
By PR Newswire
July 21, 2026 | 11:25
SuanNutra signed an agreement to acquire a portfolio of specialty natural ingredients businesses from IFF, backed by majority shareholder Carbyne Equity Partners, expanding its global science-backed ingredients portfolio.
By PR Newswire
July 21, 2026 | 11:15
B&R Technology Merger Corp priced its initial public offering of 32,500,000 units at $10.00 per unit, raising $325 million ahead of its listing on the Nasdaq Global Market.
By PR Newswire
July 21, 2026 | 10:44
Telix Pharmaceuticals reported US$247 million in second-quarter revenue for the period ended 30 June 2026, providing a market update on commercial performance and pipeline progress across its radiopharmaceutical portfolio.